plumbagin has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, R; Li, Y; Liang, X; Su, M; Yu, S | 1 |
| Gopala, S; Krishnan, N; Nadhan, R; Patra, D; Rajan, A; Ravi, D; Srinivas, P | 1 |
2 other study(ies) available for plumbagin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Medical Significance of Uterine Corpus Endometrial Carcinoma Patients Infected With SARS-CoV-2 and Pharmacological Characteristics of Plumbagin.
Topics: Adult; Aged; Aged, 80 and over; Calcium-Binding Proteins; Carcinoma, Endometrioid; Computational Biology; COVID-19; COVID-19 Drug Treatment; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Association Studies; Host-Pathogen Interactions; Humans; Membrane Proteins; Middle Aged; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Naphthoquinones; Prognosis; SARS-CoV-2; Signal Transduction; Tumor Necrosis Factor-alpha; Uterus | 2021 |
Perspectives on mechanistic implications of ROS inducers for targeting viral infections.
Topics: Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Naphthoquinones; Pandemics; Reactive Oxygen Species; RNA, Viral; SARS-CoV-2; Virus Diseases | 2021 |